Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.

Pathology international - 1 Mar 2000

Morita K, Ono Y, Fukui H, Tomita S, Ueda Y, Terano A, Fujimori T

Abstract excerpt

Clarification of the pathogenic relationships existing among ovarian cystadenomas, tumors of low malignant potential (LMP) and various adenocarcinoma types, a series of 29 mucinous and 19 serous ovarian tumors including adenomas, LMP tumors and adenocarcinomas were examined. P53 protein was detec...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Gene Expression Regulation, Neoplastic
Share to Genes, p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 10792785
DOI: 10.1046/j.1440-1827.2000.01028.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-10792785-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.PMID 10792785Read ↗

p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.Semantic proximity Read ↗

Molecular characterization of 103 ovarian serous and mucinous tumors.Semantic proximity Read ↗

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Semantic proximity Read ↗

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.Semantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.Semantic proximity Read ↗

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53.Semantic proximity Read ↗

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors.Semantic proximity Read ↗

In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential.Semantic proximity Read ↗

K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.